Showing results (391-400 of 399) with videos related to

Sort By:
Pageof 40
You have reached the last page of results.This site can display upto 399 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2002
Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphomaUlrich Kaiser, Irmgard Uebelacker, Ulrich Abel, et al.
Blood|February 24, 2007
Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemiaRüdiger Hehlmann, Ute Berger, Markus Pfirrmann, et al.
Leukemia|July 30, 2003
Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyureaR Hehlmann, U Berger, M Pfirrmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2013
Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IVRüdiger Hehlmann, Martin C Müller, Michael Lauseker, et al.
Leukemia|February 10, 2016
Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IVM B Miranda, M Lauseker, M-P Kraus, et al.
Blood|January 15, 1996
Improved outcome in adult B-cell acute lymphoblastic leukemiaD Hoelzer, W D Ludwig, E Thiel, et al.
Leukemia|October 15, 2015
Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatmentA Gratwohl, M Pfirrmann, A Zander, et al.
Haematologica|December 6, 2018
Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IVChristian Michel, Andreas Burchert, Andreas Hochhaus, et al.
Leukemia|August 15, 2017
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinantsR Hehlmann, M Lauseker, S Saußele, et al.
Pageof 40